Egea Alexandre, Dupuis Claire, de Montmollin Etienne, Wicky Paul-Henry, Patrier Juliette, Jaquet Pierre, Lefèvre Lucie, Sinnah Fabrice, Marzouk Mehdi, Sonneville Romain, Bouadma Lila, Souweine Bertrand, Timsit Jean-François
Service d'Anesthésie Réanimation, CHU Saint Antoine, APHP, Paris, France.
Service de Médecine Intensive et Réanimation, CHU Clermont Ferrand, CHU Hôpital Gabriel-Montpied, 58 Rue Montalembert, 63000, Clermont Ferrand, France.
Ann Intensive Care. 2022 Sep 26;12(1):88. doi: 10.1186/s13613-022-01058-w.
Augmented renal clearance (ARC) remains poorly evaluated in ICU. The objective of this study is to provide a full description of ARC in ICU including prevalence, evolution profile, risk factors and outcomes.
This was a retrospective, single-center, observational study. All the patients older than 18 years admitted for the first time in Medical ICU, Bichat, University Hospital, APHP, France, between January 1, 2017, and November 31, 2020 and included into the Outcomerea database with an ICU length of stay longer than 72 h were included. Patients with chronic kidney disease were excluded. Glomerular filtration rate was estimated each day during ICU stay using the measured creatinine renal clearance (CrCl). Augmented renal clearance (ARC) was defined as a 24 h CrCl greater than 130 ml/min/m.
312 patients were included, with a median age of 62.7 years [51.4; 71.8], 106(31.9%) had chronic cardiovascular disease. The main reason for admission was acute respiratory failure (184(59%)) and 196(62.8%) patients had SARS-COV2. The median value for SAPS II score was 32[24; 42.5]; 146(44%) and 154(46.4%) patients were under vasopressors and invasive mechanical ventilation, respectively. The overall prevalence of ARC was 24.6% with a peak prevalence on Day 5 of ICU stay. The risk factors for the occurrence of ARC were young age and absence of cardiovascular comorbidities. The persistence of ARC during more than 10% of the time spent in ICU was significantly associated with a lower risk of death at Day 30.
ARC is a frequent phenomenon in the ICU with an increased incidence during the first week of ICU stay. Further studies are needed to assess its impact on patient prognosis.
在重症监护病房(ICU)中,强化肾清除率(ARC)仍未得到充分评估。本研究的目的是全面描述ICU中的ARC,包括患病率、演变情况、危险因素和预后。
这是一项回顾性、单中心观察性研究。纳入2017年1月1日至2020年11月31日期间首次入住法国巴黎公立医院集团比沙医院医学ICU且年龄大于18岁、入住ICU时间超过72小时并被纳入Outcomerea数据库的所有患者。排除慢性肾脏病患者。在ICU住院期间,每天使用实测肌酐清除率(CrCl)估算肾小球滤过率。强化肾清除率(ARC)定义为24小时CrCl大于130 ml/min/m²。
共纳入312例患者,中位年龄为62.7岁[51.4;71.8],106例(31.9%)患有慢性心血管疾病。入院的主要原因是急性呼吸衰竭(184例(59%)),196例(62.8%)患者感染了SARS-CoV-2。简化急性生理学评分(SAPS)II的中位数为32[24;42.5];分别有146例(44%)和154例(46.4%)患者使用血管活性药物和有创机械通气。ARC的总体患病率为24.6%,在ICU住院第5天患病率达到峰值。ARC发生的危险因素是年轻和无心血管合并症。在ICU停留时间超过10%的时间内持续存在ARC与第30天较低的死亡风险显著相关。
ARC在ICU中是一种常见现象,在ICU住院的第一周发病率增加。需要进一步研究以评估其对患者预后的影响。